Vimarsana
Biggest News Aggregation in the World

Rare Tumor Program News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Rare Tumor Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Rare Tumor Program Today - Breaking & Trending Today

Phase I clinical trial of new blocking antibody therapy shows promising results for the treatment of advanced medulloblastoma - Vimarsana News

Phase I clinical trial of new blocking antibody therapy shows promising results for the treatment of advanced medulloblastoma

Effective and safe treatments are needed for medulloblastoma-;the most common type of cancerous brain tumor in children-;especially for patients whose cancer has spread to the spinal cord.

Oncurious NV Reports Encouraging Data from Phase 1 Dose Escalation Study of TB-403 in ... - Vimarsana News

Oncurious NV Reports Encouraging Data from Phase 1 Dose Escalation Study of TB-403 in ...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Oncurious NV Reports Encouraging Data from Phase 1 Dose Escalation Study of TB-403 in ... Oxurion NVApril 12, 2021 GMT Leuven, Belgium, Boston, MA, US, 12 April 2021 – 7.30 AM CET – ONCURIOUS NV, a Belgium-based biotech company focused on developing innovative oncology treatments, today announces that encouraging data from a Phase 1 dose escalation study of TB-403 in pediatric subjects with relapsed or refractory medulloblastoma (MB), was presented at the annual meeting of the American Associat...

Source: apnews.com
ONCURIOUS Presenting Clinical and Preclinical Data at Upcoming American Association for Cancer ... - Vimarsana News

ONCURIOUS Presenting Clinical and Preclinical Data at Upcoming American Association for Cancer ...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. ONCURIOUS Presenting Clinical and Preclinical Data at Upcoming American Association for Cancer ... Oxurion NVApril 9, 2021 GMT Oral presentation of Phase 1 dose escalation study of TB-403 in pediatric subjects with relapsed or refractory medulloblastoma (MB) Poster presentation of research findings of best therapeutic approach to target CCR8 expressed on tumor regulatory T cells to boost anti-tumor immune responses  Leuven, Belgium 9th April 2021 – 7.30 AM CET – ONCURIOUS NV, a Belgium-based b...

Source: apnews.com